Kim A Kane-McGuire

Title: Kim A Kane-McGuire: Innovator in Cardiovascular Therapeutics

Introduction

Kim A Kane-McGuire is a prominent inventor based in Belmont, California. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target platelet ADP receptors. With a total of three patents to her name, her work is crucial in the prevention and treatment of cardiovascular diseases.

Latest Patents

Her latest patents focus on novel compounds of formulae (I) to (VIII), which include various derivatives such as sulfonylurea, sulfonylthiourea, sulfonylguanidine, sulfonylcyanoguanidine, thioacylsulfonamide, and acylsulfonamide derivatives. These compounds are recognized as effective platelet ADP receptor inhibitors. They can be utilized in various pharmaceutical compositions and are particularly effective for preventing and treating cardiovascular diseases related to thrombosis. The invention also outlines a method for preventing or treating thrombosis in mammals by administering a therapeutically effective amount of these compounds or their pharmaceutically acceptable salts.

Career Highlights

Kim A Kane-McGuire is currently associated with Portola Pharmaceuticals, Inc., where she continues to innovate in the field of cardiovascular therapeutics. Her work has been instrumental in advancing the understanding and treatment of thrombosis-related conditions.

Collaborations

Throughout her career, she has collaborated with notable colleagues, including Robert M Scarborough and Wolin Huang. These collaborations have further enhanced her research and development efforts in the pharmaceutical industry.

Conclusion

Kim A Kane-McGuire is a trailblazer in the field of cardiovascular therapeutics, with her innovative patents paving the way for new treatment options. Her contributions are vital for improving patient outcomes in cardiovascular health.